Description
BMS-986260 is a selective, and orally bioavailable TGFbetaR1 inhibitor(IC50 = 1.6 nM). BMS-986260 demonstrated functional activity in multiple TGFbeta-dependent cellular assays, excellent kinome selectivity, favorable pharmacokinetic properties, and curative in vivo efficacy in combination with anti-PD-1 antibody in murine colorectal cancer (CRC) models